Media Release Planegg/Munich, Germany, and Boston Massachussetts, November 15, 2019 MorphoSys Continues to Build Commercial Presence by Opening new U.S. Headoffice MorphoSys (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today the opening of its new U.S. headoffice. Based in Boston, MA, one of the world`s leading innovation and biotech hubs, the new location will enable MorphoSys to establish and expand its U.S. presence in advance of the potential commercialization of it first wholly-owned drug candidate, tafasitamab. Robert Coughlin, CEO of the Massachusetts Biotechnology Council (Mass BIO), members from the Boston Mayor`s Office, and members from the...
|
